Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(9-10):1519–1521. doi: 10.1038/sj.bjc.6690242

Elevated reticulocyte count – a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report

S Serke 1, H Riess 1, H Oettle 1, D Huhn 1
PMCID: PMC2362733  PMID: 10188900

Abstract

In adults, the haemolytic-uraemic syndrome (HUS) is associated with probable causative factors in the minority of all cases. Cytotoxic drugs are one of these potential causative agents. Although metastatic cancer by itself is a recognized risk-factor for the development of HUS, therapy with mitomycin-C, with cis-platinum, and with bleomycin carries a significant, albeit extremely small, risk for the development of HUS, compared with all other cytotoxic drugs. Gemcitabine is a novel cytotoxic drug with promising activity against pancreatic adenocarcinoma. We are reporting on one patient with metastatic duodenal papillary carcinoma developing HUS while on weekly gemcitabine therapy. The presenting features in this patient were non-cardiac pulmonary oedema, renal failure, thrombocytopenia and haemolytic anaemia. The diagnosis of HUS was made on the day of admission of the patient to this institution. Upon aggressive therapy, including one single haemodialysis and five plasmaphereses, the patient recovered uneventfully, with modestly elevated creatinine-values as a remnant of the acute illness. Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS. © 1999 Cancer Research Campaign

Keywords: gemcitabine, haemolytic-uraemic syndrome (HUS), pulmonary oedema

Full Text

The Full Text of this article is available as a PDF (62.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson H., Lund B., Bach F., Thatcher N., Walling J., Hansen H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Sep;12(9):1821–1826. doi: 10.1200/JCO.1994.12.9.1821. [DOI] [PubMed] [Google Scholar]
  2. BRAIN M. C., DACIE J. V., HOURIHANE D. O. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Haematol. 1962 Oct;8:358–374. doi: 10.1111/j.1365-2141.1962.tb06541.x. [DOI] [PubMed] [Google Scholar]
  3. Brodowicz T., Breiteneder S., Wiltschke C., Zielinski C. C. Gemcitabine-induced hemolytic uremic syndrome: a case report. J Natl Cancer Inst. 1997 Dec 17;89(24):1895–1896. doi: 10.1093/jnci/89.24.1895. [DOI] [PubMed] [Google Scholar]
  4. Casper E. S., Green M. R., Kelsen D. P., Heelan R. T., Brown T. D., Flombaum C. D., Trochanowski B., Tarassoff P. G. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12(1):29–34. doi: 10.1007/BF00873232. [DOI] [PubMed] [Google Scholar]
  5. Conlon P. J., Howell D. N., Macik G., Kovalik E. C., Smith S. R. The renal manifestations and outcome of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in adults. Nephrol Dial Transplant. 1995;10(7):1189–1193. [PubMed] [Google Scholar]
  6. Cortes-Funes H., Martin C., Abratt R., Lund B. Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs. 1997 Jul;8(6):582–587. doi: 10.1097/00001813-199707000-00005. [DOI] [PubMed] [Google Scholar]
  7. Crocker J., Jones E. L. Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma. J Clin Pathol. 1983 Jan;36(1):24–29. doi: 10.1136/jcp.36.1.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dobbie M., Hofer S., Oberholzer M., Herrmann R. Veno-occlusive disease of the liver induced by gemcitabine. Ann Oncol. 1998 Jun;9(6):681–681. doi: 10.1023/a:1008225930573. [DOI] [PubMed] [Google Scholar]
  9. Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996 Jun;72(6):341–348. doi: 10.1007/s002770050184. [DOI] [PubMed] [Google Scholar]
  10. Green M. R. Gemcitabine safety overview. Semin Oncol. 1996 Oct;23(5 Suppl 10):32–35. [PubMed] [Google Scholar]
  11. Groff J. A., Kozak M., Boehmer J. P., Demko T. M., Diamond J. R. Endotheliopathy: a continuum of hemolytic uremic syndrome due to mitomycin therapy. Am J Kidney Dis. 1997 Feb;29(2):280–284. doi: 10.1016/s0272-6386(97)90042-1. [DOI] [PubMed] [Google Scholar]
  12. Gulati S. C., Sordillo P., Kempin S., Reich L., Magill G. B., Scheiner E., Clarkson B. Microangiopathic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouracil. Cancer. 1980 May 1;45(9):2252–2257. doi: 10.1002/1097-0142(19800501)45:9<2252::aid-cncr2820450906>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  13. Keller F., Schwarze H., Schwarz A. Klinisches Vorgehen bei hämolytisch-urämischem Syndrom und thrombotisch-thrombozytopenischer Purpura (HUS-TTP). Wien Klin Wochenschr. 1994;106(19):603–607. [PubMed] [Google Scholar]
  14. Kienast J., Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood. 1990 Jan 1;75(1):116–121. [PubMed] [Google Scholar]
  15. Matsumae T., Takebayashi S., Naito S. The clinico-pathological characteristics and outcome in hemolytic-uremic syndrome of adults. Clin Nephrol. 1996 Mar;45(3):153–162. [PubMed] [Google Scholar]
  16. Nordström B., Strang P. Microangiopathic hemolytic anemias (MAHA) in cancer. A case report and review. Anticancer Res. 1993 Sep-Oct;13(5C):1845–1849. [PubMed] [Google Scholar]
  17. Sens Y. A., Miorin L. A., Silva H. G., Malheiros D. M., Filho D. M., Jabur P. Acute renal failure due to hemolytic uremic syndrome in adult patients. Ren Fail. 1997 Mar;19(2):279–282. doi: 10.3109/08860229709026289. [DOI] [PubMed] [Google Scholar]
  18. Tonato M., Mosconi A. M., Martin C. Safety profile of gemcitabine. Anticancer Drugs. 1995 Dec;6 (Suppl 6):27–32. doi: 10.1097/00001813-199512006-00005. [DOI] [PubMed] [Google Scholar]
  19. Verwey J., de Vries J., Pinedo H. M. Mitomycin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer Clin Oncol. 1987 Feb;23(2):195–199. doi: 10.1016/0277-5379(87)90014-9. [DOI] [PubMed] [Google Scholar]
  20. Zeigler Z. R., Rosenfeld C. S., Andrews D. F., 3rd, Nemunaitis J., Raymond J. M., Shadduck R. K., Kramer R. E., Gryn J. F., Rintels P. B., Besa E. C. Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in Adult Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM). Am J Hematol. 1996 Dec;53(4):213–220. doi: 10.1002/(SICI)1096-8652(199612)53:4<213::AID-AJH1>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES